HYPOCON tests biphasic chemoradiotherapy to target hypoxia in head and neck cancer
HYPOCON will test 40 Gy/20 fractions followed by 15 Gy/3 against 55 Gy/20, both with concurrent cisplatin.
Tag
The Radiation Oncology Feed
For radiation oncologists · physicists · RTTs · dosimetrists